Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/4/2025

Factors Affecting HbA1c Measurements

Conditions That Shorten RBC Lifespan

  • Hemolytic anemia of any etiology falsely lowers HbA1c by reducing the time available for hemoglobin glycation, according to the American Diabetes Association 1, 3
  • Recovery from acute blood loss decreases mean RBC age, leading to spuriously low results, as reported by the American Diabetes Association 1, 2
  • Recent blood transfusion introduces younger donor red blood cells with less accumulated glycation, as noted by the American Diabetes Association 4, 3
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency increases red cell turnover and can lower HbA1c by approximately 0.8% in homozygous men and 0.7% in homozygous women, according to the American Diabetes Association 4, 3, 5

Conditions That Increase RBC Production

  • Erythropoietin therapy stimulates production of younger red blood cells with less accumulated glycation, as reported by the American Diabetes Association 4, 3, 5
  • Iron supplementation and vitamin B12 therapy increase erythrocyte production, introducing younger cells into circulation, according to the European Association for the Study of Diabetes 6
  • Second and third trimesters of pregnancy show slightly lower HbA1c levels due to increased red blood cell turnover, as noted by the American Diabetes Association 4, 7, 6

Hemoglobin Variants and Genetic Factors

  • Sickle cell trait (HbS heterozygosity) in African Americans lowers HbA1c by approximately 0.3% for any given level of mean glycemia, according to the American Diabetes Association 4, 7, 3
  • Homozygous hemoglobin variants (HbSS, HbEE) prevent accurate HbA1c measurement entirely, as reported by the American Diabetes Association 1, 2

Medication and Supplement Interference

  • Vitamins C and E are reported to falsely lower HbA1c results, possibly by inhibiting glycation of hemoglobin, according to the American Diabetes Association 1, 2

End-Stage Renal Disease

  • Hemodialysis patients demonstrate discrepancies between HbA1c and true mean glycemia due to altered RBC turnover, as noted by the American Diabetes Association 4, 3

Clinical Implications and Management

  • When HbA1c is unexpectedly low or discordant with plasma glucose measurements, use plasma glucose criteria alone for diagnosis and monitoring, as recommended by the American Diabetes Association 7, 5
  • Fructosamine or glycated albumin should be used when abnormalities in red blood cell turnover compromise HbA1c interpretation, though they reflect a shorter period (2-4 weeks) of average glycemia, according to the American Diabetes Association 1, 2, 5
  • Self-monitoring of blood glucose (SMBG) provides direct glucose measurements unaffected by RBC turnover, as noted by the American Diabetes Association 5
  • Continuous glucose monitoring (CGM) offers comprehensive glycemic assessment when available, according to the American Diabetes Association 5

Laboratory Considerations

  • Laboratories must use only NGSP-certified HbA1c assay methods traceable to the DCCT reference, as recommended by the American Diabetes Association 1, 7
  • Marked discrepancies between measured HbA1c and plasma glucose levels should prompt consideration that the assay may be unreliable for that individual, according to the American Diabetes Association 7
  • Boronate affinity chromatography methods may be more reliable in the presence of interfering factors, as noted by the American Diabetes Association 5